enzalutamide – Talk Bio

FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo

2 weeks ago talkbio0Tagged Advisory Committees, enzalutamide, expansion, Inhibitor, Labels (device), Malignant neoplasm of prostate, mCRPC, PARP1 gene, Pfizer, talazoparib, Talzenna, unanimous vote, United States Food and Drug Administration

FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote

ESSA Pharma Terminates Masofaniten Development After Phase 2 Trial Failure in Prostate Cancer

7 months ago talkbio0Tagged Clinical Trial Termination, enzalutamide, ESSA, Malignant neoplasm of prostate, masofaniten, Pharma, Phase 2 trial

ESSA Pharma, Masofaniten, Prostate Cancer, Phase 2 Trial, Enzalutamide, Xtandi, Clinical Trial Termination

Comparative Efficacy of J&J’s Erleada and Astellas/Pfizer’s Xtandi in Non-Metastatic Prostate Cancer: Real-World Study Insights

8 months ago talkbio0Tagged apalutamide, Comparative Efficacy, enzalutamide, Erleada, Malignant neoplasm of prostate, nmCRPC, non-metastatic castration-resistant prostate cancer, profiles, Real-World Study, Safety

Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), Erleada (Apalutamide), Xtandi (Enzalutamide), Real-World Study, Comparative Efficacy, Safety Profiles